Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 17/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206179 | 0.86 | LRRK2 (0.56) | LRRK2ALK | |
| SCHEMBL2034102 | 0.83 | LRRK2 (0.58) | LRRK2ALKAURKAKDR | |
| SCHEMBL380422 | 0.82 | LRRK2 (0.64) | LRRK2 | |
| SCHEMBL2637335 | 0.81 | LRRK2 (0.49) | LRRK2ALK | |
| SCHEMBL1613768 | 0.81 | EGFR (0.53) | LRRK2ALK | |
| SCHEMBL2637336 | 0.80 | LRRK2 (0.48) | LRRK2ALK | |
| SCHEMBL21723720 | 0.79 | LRRK2 (0.48) | LRRK2ALKAURKAKDRAURKB | |
| SCHEMBL10205824 | 0.79 | ALK (0.69) | ALK | |
| SCHEMBL15226716 | 0.79 | LRRK2 (0.58) | LRRK2 | |
| SCHEMBL2033545 | 0.79 | LRRK2 (0.50) | LRRK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | INCHEON NATIONAL UNIVERSITY RESEARCH & BUSINESS FOUNDATION (KR) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | PTK2, DAPK2, DAPK1 | LRRK2 701/4885ALK 404/4885AURKA 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.